The Bull Rankings scorecard — our quality-growth score is 87.8 / 100, built from three pillars each graded 0–100 against sector peers: Quality 81, Growth 96, Value 88. At today's price, our reverse-DCF read says the market is implicitly betting on about 8% a year in free-cash-flow growth sustained for a decade — a gauge of how much optimism is already in the stock.
The thesis
Neurocrine is a high‑growth compounder that the market is already pricing for optimism. As of the quarter ended 2026‑06‑30 the stock trades at a PE of 22.5 and a PEG of 0.45, while delivering a 20.9% profit margin and 19.1% ROE. Our Bull Rankings model awards NBIX an 87.8/100 quality‑growth score, with Growth (96) as the strongest pillar and Quality (81) as the weakest. The growth pillar justifies a bullish narrative, but the modest quality rating warns that the current price already assumes the company can sustain its rapid revenue expansion.
What the business actually is
Neurocrine discovers, develops and commercializes drugs for neurological, psychiatric, endocrine and immunological disorders. Its cash‑generating franchise centers on four FDA‑approved products: INGREZZA for tardive dyskinesia and Huntington’s chorea, Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia. These therapies are sold primarily to U.S. specialty physicians and hospital formularies, with a growing international footprint. The pipeline—NBI‑1076986 (movement disorders), Osavampator (treatment‑resistant depression) and NBI‑1117568—feeds the same therapeutic clusters, promising incremental sales once they clear pivotal trials.
Why it can keep compounding
The company’s 20.9% profit margin and 19.1% ROE signal durable returns on capital, especially given a debt‑to‑equity of 0.12 and a beta of 0.39, which underscores low financial risk. Our model’s “Durable high returns” signal rests on the moat created by INGREZZA’s first‑in‑class status for tardive dyskinesia—a niche with few competitors and a high barrier to entry due to the drug’s complex mechanism and extensive safety data. Orilissa and Oriahnn enjoy specialty‑market exclusivity and reimbursement pathways that are hard to replicate quickly. The pipeline’s focus on neurologic and endocrine indications leverages existing sales forces and regulatory expertise, reinforcing the growth engine without diluting the core franchise.
The valuation question
At $154.23 the stock sits below its 52‑week high of $186.12 but still commands a PE of 22.5. Our reverse‑DCF shows the current price implies ~8% annual free‑cash‑flow growth for ten years. That figure is markedly lower than the 34.4% FY YoY revenue growth reported, suggesting the market is discounting future expansion—perhaps because the growth pillar is already near‑maxed or because upcoming patent cliffs could erode margins. The analyst consensus target of $211.57 (mean recommendation 1.44, “strong_buy”) reflects a ~37% upside, which would require the implied FCF growth to accelerate well beyond the 8% baseline, essentially betting on the pipeline delivering sizable revenue streams soon. In other words, the price is not overly optimistic; it leaves room for upside if growth sustains.
The bear case
The weakest pillar—Quality at 81—signals that the business’s operational excellence may be vulnerable. A debt‑to‑equity of 0.12 is comforting, yet the free‑cash‑flow of $870 m could be pressured if new launches demand heavy marketing spend or if INGREZZA faces generic competition within the next few years. The “Diluting shareholders” signal warns that equity issuances could dilute earnings, a risk underscored by recent modest purchases from investors like Focus Partners and ABN AMRO but no large buy‑backs. If the pipeline stalls—e.g., Osavampator fails to meet its primary endpoint—revenue growth could revert to the sector norm, making the 8% implied FCF growth appear overly generous and the stock vulnerable to a correction toward its 52‑week low of $122.14.
What would change our mind
First, a quarterly revenue growth rate that falls below 34.4% would confirm that the figure was a one‑off and would pressure the PEG further, turning the valuation bearish. Second, a decline in profit margin below 20.9%—perhaps from aggressive launch spending—would erode the quality score and validate the “Diluting shareholders” concern. Third, any significant equity issuance that pushes the debt‑to‑equity above 0.12 would signal capital‑raising pressure and could trigger a reassessment of the durable‑returns narrative. Conversely, a new product approval that adds at least $870 m of annual free cash flow would lift the growth pillar even higher, making the current 8% implied FCF growth look like a bargain and reinforcing the bullish case.